welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study
study id #: NCT01725490
condition: Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP) leads to adenomas and eventual adenocarcinomas in colon and less frequently, duodenum. Chemopreventive strategies have been studied in FAP patients to delay the development of adenomas and cancers. The non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitor have shown the regression of colorectal and duodenal adenomas in FAP patients. However, these drugs showed gastrointestinal damage and cardiovascular risks, and new preventive strategies are needed. Metformin, a biguanide, which is widely used for treating diabetes mellitus, has recently been suggested to have a suppressive effect on tumorigenesis via mTOR-inhibiting pathway, and have no significant safety issues in long term use. The investigators devised a double-blind randomized controlled trial to evaluate the effect of metformin on polyps of colorectum and duodenum in non-diabetic FAP patients.
intervention: Drug: metformin
start date: November 2012
estimated completion: August 2019
last updated: March 19, 2019
phase of development: Phase 2
size / enrollment: 100
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
- the mean percentage change of the number and size of polyps in colon and/or duodenum. [ Time Frame: After seven-month administration of metformin/placebo, colonoscopy/sigmoidoscopy and upper gastrointestinal endoscopy will be performed. ] [ Designated as safety issue: No ]
At the base-line endoscopy, India-ink tattoo will be placed in the ascending colon, sigmoid colon/rectum, and duodenum. In case of patient with retained rectum after colectomy and ileorectal anastomosis, sigmoidoscopy will be performed. The base-line and seven-month endoscopic examination will be recorded, and photographs will be taken at the tattoo-marked area and used for measurements of the number and size of polyps. The diameter of a polyp will be measured with the aid of biopsy forceps included in the photographic field, and only distinct polyps at least 2 mm in diameter will be counted.
• Eligible Sexes: all
• FAP patients who have colonic or duodenal polyp
• FAP patients who have five or more polyps 2mm or more in diameter in endoscopic examination.
• FAP patients who had a history of colectomy within the previous 12 months or need to undergo colectomy within 8 months after randomization.
• FAP patients with malignant disease, including colorectal cancer.
• FAP patients who used NSAIDs (non-steroidal anti-inflammatory drugs) or aspirin three or more times a week within 6 months of randomization.
• FAP patients with diabetes mellitus.
• Pregnant or breast-feeding patients.
• Patients with abnormal results of serum laboratory tests (renal function and liver function test) and significant infectious or respiratory diseases.
expertly curated content related to this topic
- Familial Adenomatous Polyposis by Douglas Riegert Johnsonhttp://www.slideshare.net/douglasriegert...
- A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Ad...Evidence supporting aspirin and resistan...
- Bonnies Diary March 08https://jtvcancersupport.com/embed/46053...
- Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical TrialsThis chapter briefly summarizes the curr...
- Special Concerns for People with J-PouchesAfter having an ileoanal reservoir proce...
- Sirolimus and Familial Adenomatous Polyposis (FAP)The aim of the study is to investigate t...
- Gardner Syndrome: Skin Manifestations, Differential Diagnosis and ManagementGardner syndrome is a variant of familia...